1.31
price up icon3.97%   0.05
after-market Handel nachbörslich: 1.37 0.06 +4.58%
loading
Schlusskurs vom Vortag:
$1.26
Offen:
$1.26
24-Stunden-Volumen:
499.55K
Relative Volume:
1.38
Marktkapitalisierung:
$107.95M
Einnahmen:
$38.70M
Nettoeinkommen (Verlust:
$-142.66M
KGV:
-0.4816
EPS:
-2.72
Netto-Cashflow:
$-98.18M
1W Leistung:
-7.09%
1M Leistung:
-7.75%
6M Leistung:
-9.66%
1J Leistung:
-20.61%
1-Tages-Spanne:
Value
$1.25
$1.39
1-Wochen-Bereich:
Value
$1.20
$1.43
52-Wochen-Spanne:
Value
$1.05
$3.77

Adicet Bio Inc Stock (ACET) Company Profile

Name
Firmenname
Adicet Bio Inc
Name
Telefon
617-482-2333
Name
Adresse
131 DARTMOUTH STREET, BOSTON
Name
Mitarbeiter
143
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
ACET's Discussions on Twitter

Adicet Bio Inc Stock (ACET) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-06-27 Herabstufung Guggenheim Buy → Neutral
2023-06-27 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2023-06-01 Herabstufung JP Morgan Overweight → Neutral
2022-09-21 Eingeleitet JP Morgan Overweight
2022-03-31 Eingeleitet SMBC Nikko Outperform
2022-03-08 Eingeleitet Truist Buy
2022-03-04 Eingeleitet Jefferies Buy
2021-05-18 Eingeleitet BTIG Research Buy
2021-04-23 Eingeleitet H.C. Wainwright Buy
2021-04-14 Eingeleitet Canaccord Genuity Buy
2021-04-08 Eingeleitet Guggenheim Buy
2020-11-04 Eingeleitet B. Riley Securities Buy
2020-10-27 Eingeleitet JMP Securities Mkt Outperform
2020-10-16 Eingeleitet Wedbush Outperform
Alle ansehen

Adicet Bio Inc Aktie (ACET) Neueste Nachrichten

pulisher
07:00 AM

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024 - StockTitan

07:00 AM
pulisher
Nov 01, 2024

Adicet Bio to Participate in Upcoming Investor Conferences - StockTitan

Nov 01, 2024
pulisher
Oct 31, 2024

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Oct 31, 2024
pulisher
Oct 18, 2024

HC Wainwright Reiterates Neutral Rating for Adicet Bio (NASDAQ:ACET) - Defense World

Oct 18, 2024
pulisher
Oct 17, 2024

Adicet Bio shares maintain Neutral rating after FDA IND amendment - Investing.com India

Oct 17, 2024
pulisher
Oct 17, 2024

Adicet Bio shares maintain Neutral rating after FDA IND amendment By Investing.com - Investing.com Australia

Oct 17, 2024
pulisher
Oct 17, 2024

Adicet Bio Advances FDA-Approved Autoimmune Therapy Trials - Yahoo Finance

Oct 17, 2024
pulisher
Oct 16, 2024

Adicet Bio (NASDAQ:ACET) Receives Neutral Rating from HC Wainwright - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

FDA greenlights Adicet Bio's trial expansion for autoimmune diseases - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome - StockTitan

Oct 16, 2024
pulisher
Oct 15, 2024

Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Down 11.0% in September - MarketBeat

Oct 15, 2024
pulisher
Oct 13, 2024

Adicet Bio, Inc. (NASDAQ:ACET) Shares Bought by Cubist Systematic Strategies LLC - MarketBeat

Oct 13, 2024
pulisher
Oct 08, 2024

Adicet Bio (NASDAQ:ACET) Raised to "Hold" at StockNews.com - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

Millennium Management LLC Adjusts Stake in Adicet Bio Inc - GuruFocus.com

Oct 08, 2024
pulisher
Oct 04, 2024

Renaissance Technologies LLC Has $1.83 Million Stock Holdings in Adicet Bio, Inc. (NASDAQ:ACET) - MarketBeat

Oct 04, 2024
pulisher
Oct 03, 2024

Adicet Bio Inc’s Shares Reel: 36.70% Quarterly Revenue Decline Amid 122.78M Market Cap - The InvestChronicle

Oct 03, 2024
pulisher
Oct 03, 2024

Did Adicet Bio Inc (ACET) perform well in the last session? - US Post News

Oct 03, 2024
pulisher
Oct 03, 2024

Adicet Bio, Inc.'s (NASDAQ:ACET) large institutional owners must be happy as stock continues to impress, up 11% over the past week - Simply Wall St

Oct 03, 2024
pulisher
Oct 02, 2024

Recent Insider Activity Suggests Potential Gains for Adicet Bio Inc (ACET) - Knox Daily

Oct 02, 2024
pulisher
Oct 01, 2024

Adicet Bio stock maintains neutral rating amid lupus nephritis trial - Investing.com

Oct 01, 2024
pulisher
Oct 01, 2024

Stonepine Capital Management LLC Has $737,000 Holdings in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World

Oct 01, 2024
pulisher
Oct 01, 2024

Adicet Bio begins enrolling subjects in Phase I trial of autoimmune disease therapy - Clinical Trials Arena

Oct 01, 2024
pulisher
Oct 01, 2024

Stonepine Capital Management LLC Increases Stake in Adicet Bio, Inc. (NASDAQ:ACET) - MarketBeat

Oct 01, 2024
pulisher
Sep 30, 2024

Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference - Business Wire

Sep 30, 2024
pulisher
Sep 30, 2024

Adicet Bio (NASDAQ:ACET) Stock Rating Reaffirmed by HC Wainwright - MarketBeat

Sep 30, 2024
pulisher
Sep 30, 2024

Adicet Bio (NASDAQ:ACET) Now Covered by Analysts at Guggenheim - MarketBeat

Sep 30, 2024
pulisher
Sep 30, 2024

Guggenheim Begins Coverage on Adicet Bio (NASDAQ:ACET) - Defense World

Sep 30, 2024
pulisher
Sep 30, 2024

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases - BioSpace

Sep 30, 2024
pulisher
Sep 30, 2024

Adicet Bio Launches Phase 1 Trial of ADI-001, Eyes Expansion - TipRanks

Sep 30, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: Adicet Bio stock navigates competitive CAR-T waters - Investing.com

Sep 27, 2024
pulisher
Sep 25, 2024

Biomarker Data from Oncology Trial for Adicet Bio’s Gamma Delta T-cell Therapy ADI-001 Indicates Potential for Use in Autoimmune Disease - CGTLive™

Sep 25, 2024
pulisher
Sep 24, 2024

Analysts’ Weekly Ratings Changes for Adicet Bio (ACET) - Defense World

Sep 24, 2024
pulisher
Sep 21, 2024

Adicet Bio shares hold neutral rating amid positive study data By Investing.com - Investing.com South Africa

Sep 21, 2024
pulisher
Sep 20, 2024

Adicet Bio shares hold neutral rating amid positive study data - Investing.com

Sep 20, 2024
pulisher
Sep 20, 2024

Adicet Bio (NASDAQ:ACET) Earns Outperform Rating from Wedbush - MarketBeat

Sep 20, 2024
pulisher
Sep 20, 2024

Adicet Bio reports promising ADI-001 therapy data - Investing.com

Sep 20, 2024
pulisher
Sep 19, 2024

HC Wainwright Reiterates "Neutral" Rating for Adicet Bio (NASDAQ:ACET) - MarketBeat

Sep 19, 2024
pulisher
Sep 19, 2024

Adicet Bio reports promising ADI-001 therapy data By Investing.com - Investing.com Australia

Sep 19, 2024
pulisher
Sep 19, 2024

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue - BioSpace

Sep 19, 2024
pulisher
Sep 17, 2024

Short Interest in Adicet Bio, Inc. (NASDAQ:ACET) Declines By 10.3% - MarketBeat

Sep 17, 2024
pulisher
Sep 16, 2024

Adicet Bio, Inc. (NASDAQ:ACET) Shares Bought by Acadian Asset Management LLC - MarketBeat

Sep 16, 2024
pulisher
Sep 16, 2024

Adicet Bio, Inc. (NASDAQ:ACET) Shares Purchased by Acadian Asset Management LLC - Defense World

Sep 16, 2024
pulisher
Sep 14, 2024

Adicet Bio, Inc. (NASDAQ:ACET) Expected to Earn FY2026 Earnings of ($1.11) Per Share - Defense World

Sep 14, 2024
pulisher
Sep 13, 2024

Insider Selling: Kauffman Michael, Adicet Bio Inc [ACET] Director divested 5,900 shares - Knox Daily

Sep 13, 2024
pulisher
Sep 13, 2024

Adicet Bio, Inc. (NASDAQ:ACET) Forecasted to Post FY2026 Earnings of ($1.11) Per Share - MarketBeat

Sep 13, 2024
pulisher
Sep 13, 2024

ACET’s Stock Market Adventure: -19.05% YTD Growth Amidst Volatility - The InvestChronicle

Sep 13, 2024
pulisher
Sep 13, 2024

Check Out Adicet Bio Inc (ACET)’s Trade Data Rather Than the Analysts’ Views - SETE News

Sep 13, 2024
pulisher
Sep 12, 2024

Adicet Bio (NASDAQ:ACET) Given New $8.00 Price Target at Canaccord Genuity Group - Defense World

Sep 12, 2024
pulisher
Sep 12, 2024

Adicet Bio stock target cut by Canaccord Genuity on adjusted expectations - Investing.com

Sep 12, 2024

Finanzdaten der Adicet Bio Inc-Aktie (ACET)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Adicet Bio Inc-Aktie (ACET) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
ORBIMED ADVISORS LLC
Director
Jan 25 '24
Buy
2.40
3,125,000
7,500,000
7,526,359
GORDON CARL L
Director
Jan 25 '24
Buy
2.40
3,125,000
7,500,000
7,526,359
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Kapitalisierung:     |  Volumen (24h):